BioClinica Launches Websend and Creates Efficiencies for Clinical Trial Imaging Delivery
BioClinica™, Inc., (NASDAQ: BIOC) announced the release of BioClinica WebSend, a system that simplifies and accelerates image collection for clinical studies. WebSend transfers and tracks medical images in real-time, offering fast delivery of image data and enhanced data quality with fewer site queries.
BioClinica WebSend is complemented by BioClinica WebView, a solution for managing the electronic sharing, blinding, tracking, archiving and analysis of medical images for clinical trials worldwide.
“BioClinica WebSend allows any investigator site or imaging center globally to send all medical images to BioClinica electronically in a secure, regulatory-compliant manner. Along with BioClinica WebView, WebSend manages the collection and validation of those images,” said Mark L. Weinstein, CEO of BioClinica, Inc.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
